Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease - Takeaways - MDSpire

Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease

  • By

  • Zhengtai Sun

  • Yuting Liu

  • Lijuan Que

  • May 28, 2026

  • 0 min

Share

  • 1

    The study evaluated the safety of perfluorohexyloctane ophthalmic solution for dry eye disease using the FDA Adverse Event Reporting System (FAERS) database.

  • 2

    A total of 92 adverse event reports were identified, with the most common issues being product delivery mechanism problems and eye irritation.

  • 3

    The top adverse events meeting positive signal criteria included wrong dose and patient dissatisfaction with treatment.

  • 4

    The median time-to-onset for adverse events related to perfluorohexyloctane was 2 days.

  • 5

    FAERS data did not indicate major safety concerns, with reported adverse events primarily linked to the instillation process.

Original Source(s)

Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease

  • by Zhengtai Sun, Yuting Liu, Lijuan Que

  • May 28, 2026

Related Content

Dry Eye Dx and Tx: <br>Tailoring the Tear Reservoir</br>

Dry Eye Across Autoimmune Diseases

The nationwide analysis found the highest rates of dry eye disease among patients with Sjögren’s syndrome.

The Relationship of Tear Film Instability and Higher-Order Aberrations to Refractive Variability

Jade Coats, OD, discusses the effects of higher-order abberations on refractions and what to do about them.